Показано 0 из 0
Дата |
---|
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
18.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
19.09
|
22.24
|
22.18
|
22.05
|
22.26
|
22.15
|
|
|
20 337 452.50
|
14 609.00
|
22.18
|
22.75
|
22.42
|
22.23
|
22.73
|
22.25
|
|
|
29 822 078.29
|
14 994.00
|
19.31
|
22.60
|
22.55
|
22.33
|
22.58
|
22.47
|
|
|
64 278 010.38
|
14 066.00
|
22.00
|
22.60
|
22.47
|
22.34
|
22.585
|
22.53
|
|
|
35 318 890.23
|
18 287.00
|
19.11
|
22.50
|
22.21
|
22.12
|
22.475
|
22.38
|
|
|
29 818 705.46
|
16 601.00
|
22.00
|
22.40
|
22.36
|
22.095
|
22.44
|
22.26
|
|
|
38 864 610.01
|
18 517.00
|
22.06
|
22.50
|
22.21
|
22.19
|
22.55
|
22.32
|
|
|
37 494 344.37
|
18 696.00
|
21.57
|
22.50
|
21.88
|
21.84
|
22.225
|
22.20
|
|
|
127 457 267.03
|
26 678.00
|
21.07
|
22.20
|
21.44
|
21.36
|
21.82
|
21.73
|
|
|
32 948 737.61
|
18 556.00
|
19.18
|
22.07
|
21.77
|
21.483
|
21.88
|
21.56
|
|
|
36 329 045.87
|
21 243.00
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.